Seoul Semiconductor achieves 1.04 billion US$ record annual revenues for fiscal year 2017
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a market leader in LED (light emitting diode) design and manufacturing, today announced 2017 fiscal year consolidated revenues of US$ 1.04 billion. The 16% rise in consolidated revenues far exceeds the industry average, which grew 2% during the same period. The growth of revenue is contributed to improvements in both general lighting sales and IT product related sales growing in the mid-teens as well as the automotive lighting business which grew more than 20%.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180130005564/en/
Headquarters Seoul Semiconductor Co., Ltd., Ansan, South Korea (Photo: Business Wire)
The rise in revenue for the general lighting segment was largely due to an increase in sales of 220V and 370V Acrich MJT products for household and industrial applications. Other notable revenue increases were reported for WICOP, an innovative product line of package-less LEDs, as well as for the Acrich NanoDriver, which incorporates step drive methods that achieve results greater than those of conventional SMPS technology. In addition to offering these differentiated technologies, Seoul expects its SunLike natural spectrum LED technology, which may offer health benefits for human eyes, to lead the future of LED lighting and become a large contributor to the future sales and profit for the company.
Researchers who won the Nobel Prize in 2017 were recognized for their new findings of the impact of light on circadian rhythm in humans. This has proven to be an important topic in our society and generated great attention for Dr. Charles Czeisler, the Harvard professor that has dedicated his research to this particular area. He is now conducting research study with NASA on how light affects the circadian rhythms of astronauts.
According to new research, myopia (near-sightedness) increased from 20% in the 1950s to 80% in 2010 among populations in Asia. Fluorescent lights and conventional LED light sources emit a strong blue light that is known to cause eye fatigue, which may later result in retinal damage. Seoul Semiconductor, together with Toshiba Materials of Japan, has jointly developed SunLike natural spectrum LED technology, which provides lighting conditions most similar to actual sun light and can be seen as a solution that helps to protect human eyes from this potential damage.
The company provided a revenue guidance of KrW 270 to 290 billion for the first quarter of 2018. This figure is in range of 5% to 13% on a year-over-year basis. Although first quarter is normally considered to be an off-season, the company is showing a positive outlook for growth from last year for this 2018 fiscal year.
Sangbum Kim, the company’s Chief Financial Officer, has stated that fiscal year 2017 sales were a result of the company’s relentless efforts to stay ahead of competition by continuously investing in R&D and strengthening global sales organizations. In order to further accelerate revenue growth into the double digit range for 2018, the company plans to further drive sales of differentiated products such as SunLike while also shifting more focus to its rapidly growing automotive lighting business.
About Seoul Semiconductor:
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fourth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as SunLike – delivering the world’s best light quality in a next-generation LED enabling human-centric lighting optimized for circadian rhythms; Wicop – a simpler structured package-free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; NanoDriver Series – World’s Smallest 24W DC LED Drivers; Acrich, the world's first high-voltage AC-driven LED technology developed in 2005, includes all AC LED-related technologies from chip to module and circuit fabrication, as well as multi-junction technology (MJT); and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs. UCD constitutes a high color gamut display which delivers over 90 % NTSC.
For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com
Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.
Investor information and additional product details are available on the company website, www.seoulsemiconductor.com
This press release material contains forward-looking statements which reflect Seoul Semiconductor’s current views with respect to future events and financial performance, which are subject to certain risks and uncertainties which could cause actual results to differ materially from those anticipated. Although Seoul Semiconductor believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be attained. Seoul Semiconductor undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. All financial figures are consolidated unless stated otherwise.
Seoul Semiconductor Europe GmbH
Tel: +49 (0)89 450 3690-0
Seoul Semiconductor Inc.
Tel: +1 (919) 410-9856
Seoul Semiconductor Co., Ltd
Tel: +82 070.4391.8270
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Asuragen to Launch the AmplideX® PCR/CE DMPK Kit and Present Growing Genetic Testing Portfolio at 2018 European Society of Human Genetics (ESHG) Conference22.5.2018 12:00 | Pressemelding
Asuragen, Inc., a molecular diagnostics company delivering high-quality, easy to use products for complex testing in genetics and oncology, today announced the launch of the AmplideX® PCR/CE DMPK Kit* to simplify analysis of repeat expansions within the DMPK gene, which is implicated in myotonic dystrophy type I (DM1), also known as Steinert’s disease. DM1 is an inherited form of muscular dystrophy that affects the muscles as well as multiple other organ systems, and its severity is largely determined by the size of the CTG trinucleotide repeat expansion within the DMPK gene. These expansions commonly extend beyond a thousand CTG repeats and therefore have required the use of cumbersome Southern blot technology to estimate their size. “The AmplideX DMPK Kit represented a significant improvement over our existing process for analyzing large DMPK expansions,” said Doctor Sophie Rondeau, PharmD, PhD, and Professor Jean-Paul Bonnefont, MD, PhD, of the Necker-Enfants Malades Hospital in Par
Phil Brakewell Set to Lead WilsonHCG's Executive Search Efforts Across EMEA; Forbes Ranks WilsonHCG Among Best Executive Recruiting Firms22.5.2018 12:00 | Pressemelding
WilsonHCG, global leader and premium provider of innovative talent solutions, further expands its Executive Search division with the appointment of Director Phil Brakewell. Phil, who brings more than 14 years of talent acquisition leadership experience and most recently served as Head of Executive Search for ResourceBank, will be responsible for leading WilsonHCG’s efforts in the EMEA region. Prior to joining ResourceBank, Phil held consultant and resourcing leadership positions at Hitchenor Wakeford and The Caudwell Group – where he was responsible for developing the business internationally and drove innovative search solutions on behalf of a diverse range of clients. “WilsonHCG’s reputation speaks for itself,” said Phil. “WilsonHCG tailors its key service offerings – including Executive Search – to suit individual client needs, and I am thrilled to be part of such a dedicated, innovative team. The new Director position, covering EMEA, demonstrates our commitment to both Executive Se
Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 201822.5.2018 11:30 | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association (EHA) annual meeting in Stockholm, Sweden, from June 14-17, 2018. "We are proud to be sharing new and updated data around our innovative hematological therapies at EHA 2018, which further our understanding of blood cancers and other blood-related diseases and allow us to continue to have a major impact on the lives of patients," said Nadim Ahmed, President, Hematology & Oncology Franchise. "The data presented at EHA underscore the important role of immunomodulatory drugs at various stages of multiple myeloma, as well as illustrate our ongoing work in developing innovative treatment options, such as our erythroid maturation agent and CAR T cell therapies, for patients with life threatening blood disorders and cancers." At EHA this
New Research from Displaydata and Planet Retail RNG Estimates That Global Retailers Spent $104 Billion on Manually Changing Price Labels in 201722.5.2018 11:02 | Pressemelding
New research launched today by Displaydata and Planet Retail RNG reveals that inaccurate, inconsistent pricing – and a lack of digital technology in-store – is costing retailers in lost sales and consumer trust, as price-conscious shoppers seek out the best deal and better experiences online. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005419/en/ According to a new report from Displaydata and Planet Retail RNG, over two thirds of shoppers want technologies that enhance their experiences in stores. 33% want promotions sent direct to their mobile devices; 31% want Electronic Shelf Labels (ESLs) to show accurate, real-time prices, promotions, and detailed product information; and 27% want to be identified as a loyal customer. (Photo: Business Wire) The research report, Analogue to Automated: Retail in the Connected Age – which surveyed 5000 consumers and 1000 retailers – sought to understand what consumers want from ph
Now, officially Cool! Price f(x) named “Gartner® Cool Vendor in Digital Commerce”22.5.2018 10:01 | Pressemelding
Price f(x), a leader in Price Optimization & Management SaaS, has been named a “Cool Vendor in Digital Commerce” in the 2018 report by Gartner®, Inc.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005662/en/ Price f(x) is the pioneer of native Price Optimization & Management SaaS (“PO&M SaaS”) offering uniquely flexible, functionally broad and fast to implement solutions. In the report, Gartner® highlights Price f(x) as a true disruptor in this software segment through uncompromised customer-centric approach best reflected in the commercial offering of Pricing-as-a-Service (“PraaS™”). “We are devoted to simplicity, relevance and agility, but most importantly to commercial fairness. Our solution is designed, both technically and commercially, to quickly provide value to companies of any size, in any industry, in B2B, B2C as well as B2B2C. And offering all of that entirely free of implementation costs in our PraaS™ offe
Large-Scale Body Composition Study Reveals Link between Specific Fat Distributions and Metabolic Diseases22.5.2018 08:16 | Pressemelding
Specific patterns of fat distribution are linked to the presence of Coronary Heart Disease (CHD) and Type 2 Diabetes (T2D), according to a new study published in Obesity. 1 AMRA, the international leader in body composition analysis, today announced the results of a body composition study of over 6,000 subjects, stressing the need to measure and investigate several fat compartments in order to understand and develop treatments for multiple metabolic diseases. The new findings go far beyond what can be described by sex, age, lifestyle, BMI, or a single fat compartment, and have the potential to strongly impact how metabolic conditions will be prevented and managed in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180522005616/en/ The Obesity study was co-authored in collaboration between AMRA, Pfizer, Westminster University, Linköping University, and UK Biobank. The 6,000 subjects analyzed are part of the UK Bioba